Roche delivers strong performance in the first half of 2015
• Group sales up 6% at constant exchange rates1, 3% in Swiss francs
• Pharmaceuticals Division sales up 5%, driven by oncology (HER2-positive breast cancer medicines
+21%, Avastin +9%, MabThera/Rituxan +6%) and immunology (Actemra/RoActemra +25%, Xolair
+28%)
• Diagnostics Division sales up 7%, driven by Professional Diagnostics (+7%) and Molecular
Diagnostics (+12%)
• Strong demand for idiopathic pulmonary fibrosis medicine Esbriet
For full access, please click here.
Help employers find you! Check out all the jobs and post your resume.
